Press release
KalVista Pharmaceuticals Announces Publications in the Journal of Medicinal Chemistry and Xenobiotica for Sebetralstat
- The discovery and optimization of sebetralstat published in the Journal of Medicinal Chemistry - - Data on absorption, metabolism, and excretion of
About this update from Kalvista Pharmaceuticals, Inc.
[{"type":"text","content":"\n- The discovery and optimization of sebetralstat published in the Journal of Medicinal Chemistry -\n\n- Data on absorption, metabolism, and excretion of sebetralstat reported in the journal Xenobiotica -\n\n CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--\nKalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the publication of new sebetralstat data in both the Journal of Medicinal Chemistry and Xenobiotica. The Journal of Medicinal Chemistry article focuses on the medicinal chemistry KalVista conducted that led to the discovery of sebetralstat, with properties optimized for the on-demand treatment of hereditary angioedema (HAE). Data with sebetralstat showed high selectivity against related human serine proteases. This feature, together with the rapid and high plasma exposure and near-complete inhibition of plasma kallikrein (PKa) in preclinical studies, supported its progression into toxicology and ultimately clinical assessment. Sebetralstat has since advanced to phase 3 trials. In Xenobiotica, sebetralstat was shown to be rapidly absorbed into the systemic circulation (median Tmax of 0.5 hours) and demonstrated absorption, metabolism, and excretion properties that would be beneficial for on-demand treatment of HAE attacks.\n\n“These foundational papers further demonstrate the promise of sebetralstat for the on-demand treatment of HAE attacks,” said Andrew Crockett, Chief Executive Officer of KalVista. “We are excited to continue the development of sebetralstat in our phase 3 KONFIDENT trial and look forward to delivering an oral option for on-demand treatment for people living with HAE.”\n\nAdditional details can be found in the manuscripts, which are available at:\n\n\nJournal of Medicinal Chemistry https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c00921\n\n\nXenobiotica https://www.tandfonline.com/doi/full/10.1080/00498254.2022.2132187\n\n\nThe Journal of Medicinal Chemistry is a biweekly peer-reviewed medical journal published by the American Chemical Society covering research in medicinal chemistry. It is considered the pre-eminent publication for the field. Xenobiotica is a peer-reviewed medical journal that publishes comprehensive research papers on all area...